Clinical Trial Update: NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial in China is recruiting to evaluate an NMDA-enhancing treatment for cognitive dysfunction in schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• NMDA-enhancing treatment

Snippet

Sponsor: China Medical University Hospital | Conditions: Schizophrenia | Phase 2 | Status: RECRUITING